Nintedanib Accord

Nintedanib, the active ingredient in Nintedanib Accord, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats idiopathic pulmonary fibrosis and certain non‑small cell lung cancers in adult patients.

GNH USA supplies Nintedanib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib is used to target fibrotic and oncologic pathways in the following conditions:

Idiopathic pulmonary fibrosis: slows the decline in lung function and reduces disease progression. Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis. Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening of fibrosis.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates potential liver injury. - Bleeding events: includes gastrointestinal or other hemorrhage. - Cardiovascular events: such as hypertension or arterial thromboembolism. - Severe infections: opportunistic or serious bacterial infections. - Gastrointestinal perforation: rare but life‑threatening. - Severe skin reactions: including Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

Monitor liver function: perform baseline and periodic hepatic enzyme tests. Assess cardiovascular risk: evaluate blood pressure and history of thrombotic disease. Evaluate bleeding risk: review concomitant anticoagulant or antiplatelet use. Use caution in gastrointestinal disorders: patients with ulcer disease may have higher perforation risk. Store below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nintedanib exposure. - Anticoagulants (e.g., warfarin): increase bleeding risk. - Antiplatelet agents (e.g., clopidogrel): may potentiate hemorrhagic events.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels. - Diuretics (e.g., furosemide): can enhance renal excretion and affect fluid balance. - Statins (e.g., simvastatin): may increase risk of liver enzyme elevation.